Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06626919
PHASE1

A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases

Sponsor: Arcellx, Inc.

View on ClinicalTrials.gov

Summary

A Phase 1 dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of anito-cel in subjects with generalized myasthenia gravis (GMG). Anitocabtagene autoleucel (anito-cel) is a BCMA-directed CAR-T cell therapy.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2025-04-30

Completion Date

2028-04

Last Updated

2026-02-25

Healthy Volunteers

No

Interventions

BIOLOGICAL

anito-cel

Anitocabtagene autoleucel BCMA directed CAR T-cell therapy using a novel, synthetic binding domain, called a D-Domain

DRUG

Standard Lymphodepletion regimen

Standard lymphodepletion regimen subject receive 5 days prior to CAR T infusion

Locations (13)

UCLA Medical Center

Los Angeles, California, United States

University of California, Irvine

Orange, California, United States

Stanford Hospital

Palo Alto, California, United States

University of South Florida - Carol and Frank Morsani Center of Advanced Healthcare

Tampa, Florida, United States

Karmanos Cancer Institute

Detroit, Michigan, United States

University of Minnesota Delaware Clinical Research Unit

Minneapolis, Minnesota, United States

Mayo Clinic

Rochester, Minnesota, United States

Columbia University Irving Medical Center

New York, New York, United States

Ohio State University

Columbus, Ohio, United States

Oregon Health & Science University (OHSU)

Portland, Oregon, United States

Temple University Hospital

Philadelphia, Pennsylvania, United States

UT Southwestern Medical Center

Dallas, Texas, United States

Houston Methodist Hospital

Houston, Texas, United States